As a part of clinical outcome trials on the efficacy of combination therapy with dapagliflozin and omega-3 carboxylic acids in T2D patients with NAFLD, Eriksson et al. [156] briefly demonstrated the association between PNPLA3 rs738409 C > G genotype and therapeutic responses in different treatment groups. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.